Telix Pharmaceuticals Ltd SEC filings TLX

Telix Pharmaceuticals Ltd has 109 filings in SEC EDGAR's recent list, going back to Jan 25, 2024. Its latest annual report, Form 20-F, was filed on Feb 20, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Oct 29, 2026. The company's fiscal year ends on December 31.

Telix Pharmaceuticals Ltd SEC filings
Form Description Filed Period
UPLOAD Letter from the SEC Apr 23, 2026 —
CORRESP Letter to the SEC Apr 17, 2026 —
UPLOAD Letter from the SEC Apr 3, 2026 —
SEC STAFF LETTER Filing Nov 21, 2024 —
EFFECT Filing Nov 12, 2024 —
SEC STAFF ACTION Filing Nov 12, 2024 —
CERT Filing Nov 12, 2024 —
CORRESP Letter to the SEC Nov 12, 2024 —
20FR12B/A Filing Oct 30, 2024 —
SEC STAFF LETTER Filing Oct 28, 2024 —
CORRESP Letter to the SEC Oct 17, 2024 —
20FR12B Filing Oct 17, 2024 —
UPLOAD Letter from the SEC Oct 10, 2024 —
DRS Filing Sep 13, 2024 —
RW Filing Jun 14, 2024 —
RW Filing Jun 14, 2024 —
8-A12B Filing Jun 10, 2024 —
DRS/A Filing May 9, 2024 —
DRS/A Filing Apr 15, 2024 —
DRS/A Filing Mar 15, 2024 —
DRS/A Filing Feb 2, 2024 —
DRS Filing Jan 25, 2024 —

Showing 22 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
TLX (Nasdaq), TLPPF (OTC)
Fiscal year ends
December 31
Incorporated in
Australia
Headquarters
North Melbourne, Australia
SEC filer status
Large accelerated filer
SEC CIK
2007191

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.